CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection.
- Author:
Jiyeon HYEON
1
;
Soomin AHN
;
Cheol Keun PARK
Author Information
1. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ckpark@skku.edu
- Publication Type:Original Article
- Keywords:
CHD1L;
Carcinoma, hepatocellular;
Survival
- MeSH:
alpha-Fetoproteins;
Carcinoma, Hepatocellular;
Disease-Free Survival;
DNA-Binding Proteins;
Follow-Up Studies;
Humans;
Immunohistochemistry;
Joints;
Liver Neoplasms;
Multivariate Analysis;
Oncogenes;
Portal Vein;
Prognosis
- From:Korean Journal of Pathology
2013;47(1):9-15
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The gene for chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) was recently identified as a target oncogene within the 1q21 amplicon, which occurs in 46% to 86% of primary hepatocellular carcinoma (HCC) cases. However, the prognostic significance of CHD1L in HCC remains uncertain. In this study, we investigated the roles of CHD1L in the prognosis of HCC. METHODS: We investigated the expressions of CHD1L in tumor tissue microarrays of 281 primary HCC patients who underwent surgical resection using immunohistochemistry. Prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 75.6 months. RESULTS: CHD1L expression was observed in 48 of the 281 HCCs (17.1%). CHD1L expression was associated with a younger age (p=0.033), higher Edmondson grade (p=0.019), microvascular invasion (p<0.001), major portal vein invasion (p=0.037), higher American Joint Committee on Cancer T stage (p=0.001), lower albumin level (p=0.047), and higher alpha-fetoprotein level (p=0.002). Multivariate analyses revealed that CHD1L expression (p=0.027), Edmondson grade III (p=0.034), and higher Barcelona Clinic Liver Cancer stage (p<0.001) were independent predictors of shorter disease-free survival. CONCLUSIONS: CHD1L expression might be a prognostic marker of shorter disease-free survival in HCC patients after surgical resection.
